Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 8.12 SEK 0.62% Market Closed
Market Cap: 903.3m SEK
Have any thoughts about
Saniona AB?
Write Note

Saniona AB
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Saniona AB
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Saniona AB
STO:SANION
Other Receivables
kr8.3m
CAGR 3-Years
4%
CAGR 5-Years
-34%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Other Receivables
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Other Receivables
kr10.7m
CAGR 3-Years
-34%
CAGR 5-Years
-6%
CAGR 10-Years
1%
Ascendis Pharma A/S
NASDAQ:ASND
Other Receivables
€17.3m
CAGR 3-Years
-5%
CAGR 5-Years
41%
CAGR 10-Years
56%
B
Bavarian Nordic A/S
CSE:BAVA
Other Receivables
kr29.6m
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
10%
Bioporto A/S
CSE:BIOPOR
Other Receivables
kr8.9m
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Saniona AB
Glance View

Market Cap
903.3m SEK
Industry
Biotechnology

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

SANION Intrinsic Value
3.56 SEK
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Saniona AB's Other Receivables?
Other Receivables
8.3m SEK

Based on the financial report for Jun 30, 2024, Saniona AB's Other Receivables amounts to 8.3m SEK.

What is Saniona AB's Other Receivables growth rate?
Other Receivables CAGR 5Y
-34%

Over the last year, the Other Receivables growth was -5%. The average annual Other Receivables growth rates for Saniona AB have been 4% over the past three years , -34% over the past five years .

Back to Top